The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woo, C.-H.
Right arrow Articles by Kim, J.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woo, C.-H.
Right arrow Articles by Kim, J.-H.
The Journal of Immunology, 2004, 173: 6973-6980.
Copyright © 2004 by The American Association of Immunologists

Lipopolysaccharide Induces Matrix Metalloproteinase-9 Expression via a Mitochondrial Reactive Oxygen Species-p38 Kinase-Activator Protein-1 Pathway in Raw 264.7 Cells1

Chang-Hoon Woo, Jae-Hyang Lim2 and Jae-Hong Kim3

School of Life Sciences and Biotechnology, Korea University, Seoul, Korea


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We have identified a novel signaling pathway that leads to expression of matrix metalloproteinase-9 (MMP-9) in murine macrophages in response to the bacterial endotoxin, LPS. We showed that p38 kinase was essential for this induction and observed that LPS-induced MMP-9 expression was sensitive to rottlerin, a putative protein kinase C{delta} (PKC{delta}) inhibitor. However neither infection with a retrovirus expressing a dominant negative mutant of PKC{delta} nor down-regulation of PKC{delta} by prolonged PMA treatment affected MMP-9 expression, thus excluding involvement of PKC{delta}. Interestingly, LPS-induced MMP-9 expression and p38 kinase phosphorylation were shown to be suppressed by the antioxidant N-acetylcysteine and the flavoenzyme inhibitor diphenyleneiodonium chloride, but not by pyrrolidine dithiocarbamate, an NF-{kappa}B inhibitor. In addition, LPS was found to induce the production of mitochondrial reactive oxygen species (ROS) and this effect was rottlerin-sensitive, suggesting an inhibitory effect of rottlerin on mitochondrial ROS. LPS-induced MMP-9 expression and p38 kinase phosphorylation were also inhibited by rotenone, a specific inhibitor of mitochondrial complex I, supporting the role of mitochondrial ROS in LPS signaling to MMP-9. Finally, we showed that the ROS-p38 kinase cascade targets the transcription factor AP-1. Taken together, our findings identify a ROS-p38 kinase-AP-1 cascade as a novel pathway mediating LPS signaling to MMP-9 expression in macrophages.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Matrix metalloproteinases (MMPs)4 are a family of neutral endopeptidases that include interstitial collagenases, gelatinases, stromelysin, matrilysin, metalloelastase, and membrane-type MMPs (1, 2). Collectively, MMPs can degrade all the components of the extracellular matrix. By doing so, they play an important role in many biological processes, such as angiogenesis, embryogenesis, normal tissue remodeling, and wound healing. In addition, dysregulation of MMPs leads to destruction of connective tissue and various pathological inflammatory conditions (3). For example, MMPs are involved in tumor invasion and metastasis (4, 5).

MMPs are not only produced by structural cells such as fibroblasts and endothelial and epithelial cells, but also by inflammatory cells, including macrophages, lymphocytes, neutrophils, and eosinophils (6). Monocytes/macrophages are prominent at chronic inflammatory sites such as areas of arthritis, atherosclerosis, and periodontal disease, in which degradation of the connective tissue is believed to contribute substantially to the pathology of the disease. Stimulation of monocytes with LPS, a surface component of Gram-negative bacteria, induces a number of MMPs, including two prominent monocyte MMPs: MMP-1, an interstitial collagenase, and MMP-9 (gelatinase B; 92-kDa type IV collagenase). MMP-9 degrades laminin and type IV collagen, two components of the basement membrane. Thus, it is involved in the connective tissue loss associated with such chronic inflammatory diseases as asthma, pulmonary fibrosis, and chronic obstructive pulmonary disease, as well as with cancer progression. For instance, the level of MMP-9 is elevated in the bronchoalveolar lavage of asthmatic patients and gives rise to tissue remodeling of the airways (7).

The activity of MMPs is tightly regulated in terms of gene expression, spatial localization, and proenzyme activation; it is also subject to naturally occurring tissue MMP inhibitors (8). MMP-9 expression appears to be regulated by a number of different signaling pathways in different cell types. Thus, protein kinases, MAPKs, transcription factors such as NF-{kappa}B, and AP-1 have all been reported to be involved in the induction of MMPs (9, 10). Although there has been some work on the roles of NF-{kappa}B and MAPKs in the regulation of MMP-9 production by LPS, little is known of the involvement of reactive oxygen species (ROS) in the pathways leading to MMP-9 expression in monocytes/macrophages.

A growing body of evidence points to a role of oxygen-derived radicals such as superoxide anion (O2

{cjs1138}

), hydrogen peroxide (H2O2), and NO as intracellular signaling molecules (11, 12). For example, ROS can affect the expression of a number of genes in monocytes. H2O2 is reported to activate NF-{kappa}B, which regulates the expression of proinflammatory cytokines and immune mediators (13). In addition, C6-ceramide induces ROS production, leading to apoptosis via the transcription factor AP-1 (14). NADPH oxidase activation during phagocytosis is an important source of ROS in phagocytes, including macrophages. NADPH oxidase is inhibited by diphenyleneiodonium chloride (DPI) (15), and a recent report suggests that DPI is also a potent inhibitor of mitochondrial ROS production in monocytes/macrophages (16). Moreover, it has been established that mitochondrial ROS induce NF-{kappa}B, AP-1, and HIF-1 DNA binding activity in monocytes, lymphocytes, and hepatocytes, respectively (17, 18, 19). Consistent with these findings, mitochondrial ROS was suggested to mediate gene (e.g., angiotensinogen gene) expression in response to high glucose in kidney tubular cells (20). Because mitochondria generate ROS at the ubisemiqunone site, a change in mitochondrial redox could affect ROS production. We report in this paper that the induction of MMP-9 expression by LPS in Raw 264.7 cells is mediated by a mitochondria-derived ROS-p38 kinase cascade that leads to stimulation of AP-1.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents

BSA, DMSO, gelatin, LPS, and PMA were obtained from Sigma-Aldrich (St. Louis, MO). The following were obtained from Calbiochem (La Jolla, CA): GF109203X, a general PKC inhibitor (IC50 = 0.2 µM) (21); Go6976, a potent inhibitor of Ca2+-dependent PKC isozymes (IC50 = 6.2 nM) (21); rottlerin, a PKC{delta} inhibitor (IC50 = 3–6 µM) (22); calphostin C, a diacylglycerol-dependent PKC inhibitor (IC50 = 50 nM) (23); PD98059, a MAPK kinase inhibitor (IC50 = 2 µM) (24); SB203580, a p38 inhibitor (IC50 = 0.6 µM) (25); SP600125, a JNK inhibitor (IC50 = 0.19 µM) (26); pyrrolidine dithiocarbamate (PDTC), a NF-{kappa}B inhibitor (27); and rotenone, a mitochondrial complex I inhibitor (IC50 = 8–20 nM) (28). FBS, DMEM, and nonessential amino acids were obtained from Invitrogen Life Technologies (Gaithersburg, MD). Abs to p38 kinase were supplied by New England Biolabs (Beverley, CA), and Abs to MMP-9, PKC{delta}, and phospho-PKC{delta} were obtained from Cell Signaling Technology (Beverly, MA). All other chemicals were obtained from standard sources and were molecular biology grade or higher.

Cell culture

Murine Raw 264.7 macrophage cells (American Type Culture Collection, Manassas, VA; CRL 2278) were grown in DMEM supplemented with 10% heat-inactivated FBS, 0.1 mM nonessential amino acids, penicillin (50 U/ml), and streptomycin (50 µg/ml) at 37°C under a humidified 95/5% (v/v) mixture of air and CO2.

Assay of MMP-9 activity by gelatin zymography

MMP-9 activity was assessed by gelatin zymography. Briefly, we cultured cells (2 x 105 cells/12 well) for 12 h, collected culture supernatants, added Laemmli buffer without reducing agent to the supernatants, and subjected the supernatants to electrophoresis on 7.5% SDS-polyacrylamide gels containing 0.2% gelatin (v/v). To assess gelatinolytic activity, the gels were incubated for 24 h at 37°C in a buffer containing 50 mM Tris-Cl (pH 7.6), 150 mM NaCl, 5 mM CaCl2, and 200 µg/ml Brij-35 in the presence and the absence of EDTA and stained with Coomassie Brilliant Blue solution.

Measurement of MMP-9 by Western blot analysis

Levels of MMP-9 protein in culture supernatants and cell lysates were measured by Western blot assay. Briefly, culture supernatants and cell lysates were heated at 95°C for 5 min, subjected to 8% SDS-PAGE, and transferred to polyvinylidine difluoride membranes with incubation overnight at 4°C in Tris buffer containing nonfat dried milk (5%, w/v) and Tween 20 (0.01%, v/v). Subsequently, the membranes were incubated with the appropriate Abs, followed by secondary Ab (HRP-conjugated Ab), and developed by ECL as instructed by the manufacturer (Amersham Biosciences, Arlington Heights, IL).

Infection of Raw 264.7 cells with retroviral dominant negative PKC{delta} (DN-PKC{delta})

Retroviral expression vectors for vector and a kinase-deficient form of PKC{delta} (PKC{delta}-K376R) that acts a DN mutant were provided by Dr. S. J. Lee (Korea Institute of Radiological and Medical Sciences, Seoul, Korea). Raw 264.7 cells were infected with these vectors and seeded in 35-mm culture plates in DMEM supplemented with 10% FBS. pMFG and pMFG-DN-PKC{delta} were incubated with the retrovirus for 3 h at 37°C in serum-free DMEM. An equal volume of DMEM with 20% FBS was then added to increase the serum concentration to 10%, and incubation was continued for a total of 36 h. Thereafter, the cells were exposed to LPS and assayed for MMP-9, and levels of PKC{delta} were determined by Western blotting.

ROS measurement

Intracellular H2O2 was measured by 2',7'-dichlorofluorescein fluorescence (29, 30). Briefly, Raw 264.7 cells were grown for 24 h and then serum-starved for 6 h in phenol red-free DMEM supplemented with 0.5% FBS. To measure intracellular H2O2, the cells were then incubated for 30 min with the H2O2-sensitive fluorophore 2',7'-dichlorofluorescein diacetate (DCFH-DA; 10 µg/ml), which is taken up and oxidized to the fluorescent DCF by intracellular H2O2. After incubation with DCFH-DA, the cells were exposed to LPS for 30 min and immediately observed by FACSCalibur (BD Biosciences, Franklin Lakes, NJ). To measure mitochondria-generated ROS, fluorescence was excited at 488 nm, and the evoked emission was filtered with a 515-nm longpass filter.

Subcellular fractionation for mitochondrial O2

{cjs1138}

measurement

Cells were stimulated with 100 ng/ml LPS for 20 min, washed three times with ice-cold PBS, and scraped into ice-cold HES buffer (255 mM sucrose, 20 mM HEPES (pH 7.4), and 1 mM EDTA) supplemented with 100 mM sodium fluoride, 10 mM sodium pyrophosphate, 1 mM sodium vanadate, and protease inhibitors (1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mg/ml benzamidine, and 0.5 mM PMSF). Cell lysates were fractionated into plasma membrane and mitochondrial/nuclear fractions by differential centrifugation. Mitochondria-enriched intracellular membranes were released from washed mitotic cells by mechanical homogenization or freeze-thaw permeabilization and collected in the supernatant after centrifugation at 15,000 x g for 5 min. For mechanical homogenization, cells were passed through a 21-gauge needle. Superoxide production was detected by luminometer as lucigenin-derived chemiluminescence. It was measured in the presence of NADPH for 15 min and expressed as mean arbitrary light units per minute (16).

Transient transfection and reporter gene assays

Cells (2 x 105/35-mm plate) were cultured for 24 h and incubated with Lipofectamine and DNA complex (1.8 µg of DNA/plate) for 4 h. Sonicated calf thymus DNA was used to keep the concentration of DNA in each transfection mixture constant. To monitor variations in cell numbers and transfection efficiency, all clones were cotransfected with 0.4 µg of pSV40-{beta}-galactosidase, a eukaryotic expression vector containing the Escherichia coli {beta}-galactosidase (lacZ) structural gene under control of the SV40 promoter. After incubation with the Lipofectamine/DNA complex for 4 h, the cells were rinsed with PBS, incubated for 24 h in DMEM with 10% FBS, rinsed twice more with PBS, and lysed with 0.1 ml of lysing solution (0.2 M Tris-Cl with 0.1% Triton X-100, pH 7.6). The lysed cells were scraped off and spun for 1 min, their supernatants were collected, and protein and {beta}-galactosidase and luciferase activities were measured in the supernatants. Luciferase luminescence was measured with a luminometer (Turner, Palo Alto, CA; TD-20/20) and normalized to the cotransfected {beta}-galactosidase activity as previously described (30). Data are the averages of triplicate independent determinations.

Statistical analysis

Data are expressed as the mean percentage ± SD. Statistical comparisons between groups were made with Student’s t test. Values of p < 0.05 were considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
LPS induces expression of biologically active MMP-9 in Raw 264.7 cells

To determine whether LPS induces expression of MMP-9 in Raw 264.7 murine macrophage, cells were cultured in the presence of LPS, and the level of MMP-9 protein in the culture medium was determined. MMP-9 protein was not detected in supernatants of control cells cultured without LPS, whereas supernatants of LPS (12 h)-treated cells contained a substantial amount of MMP-9 protein as defined by Western blot analysis (Fig. 1, upper panel). To determine whether the MMP-9 protein released in response to LPS was biologically active, we assessed gelatinolytic activity in the culture supernatants. As shown in Fig. 1, gelatinolytic activity was not detected in the control supernatant, whereas the supernatant of LPS-treated cells had strong gelatinolytic activity 12 h post-LPS treatment (Fig. 1, lower panel). In contrast, the activity of MMP-2, which is constitutively expressed, was unchanged by LPS treatment.



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 1. LPS induces MMP-9 expression in Raw 264.7 cells. Raw 264.7 cells were incubated for the indicated periods with increasing concentrations of LPS in DMEM containing 0.5% FBS. At the times indicated, cell lysates were fractionated on 7.5% SDS-PAGE to determine the level of MMP-9 protein expression (upper panel), and the gelatinolytic activity of MMPs was determined by zymography as described in Materials and Methods (lower panel). MMP-2 is shown as a control. The data shown are representative of three independent experiments.

 
LPS induces MMP-9 expression via a p38 kinase pathway

Because MAPKs have been implicated in the induction of MMPs (31, 32), we examined the effect of LPS on MAPK activation. Cells were treated with LPS in the presence of various MAPKs inhibitors, and MMP-9 activity was assessed. As shown in Fig. 2, inhibition of p38 kinase with SB203580 (a p38 kinase inhibitor) reduced LPS-induced MMP-9 expression, and in agreement with these results, we found that LPS stimulated p38 kinase activity as detected by phosphorylation of p38 kinase. In contrast, LPS-induced activation of p38 kinase and MMP-9 activity was not affected by PD98059 (an ERK kinase inhibitor), or SP600125 (a JNK kinase inhibitor), suggesting that p38 kinase has a specific role in signaling MMP-9 expression.



View larger version (37K):
[in this window]
[in a new window]
  		FIGURE 2. LPS induces MMP-9 expression via a p38 kinase-dependent pathway. Upper panel, Cells were pretreated with 10 µM PD98059, 10 µM SB203580, or 10 µM SP600125 for 30 min before application of LPS for 12 h. Twenty microliters of the conditioned medium was subjected to 7.5% SDS-PAGE containing 0.2% gelatin, and the gelatinolytic activity of the MMP was determined by zymography as described in Materials and Methods. Lower panel, p38 kinase phosphorylation triggered by 100 ng/ml LPS for 20 min was assessed after exposing the cells to PD98059, SB203580, or SP600125 for 30 min. Immunoblots of whole cell extracts were probed with anti-phospho-p38 Ab, after which they were stripped and reprobed with anti-p38 Ab. The results are representative of three separate experiments.

 
Rottlerin inhibits LPS-induced MMP-9 expression

Next we examined the pathway upstream of p38 kinase activation. Because in certain cases induction of MMP-9 has been reported to be impaired by inhibition of PKCs (31, 32), we examined the involvement of PKCs in our system. Cells were treated with LPS alone or together with various PKC inhibitors, and MMP-9 expression was measured. Various inhibitors, such as rottlerin, were used. Rottlerin, a putative inhibitor of PKC{delta}, significantly attenuated LPS-induced MMP-9 expression as well as p38 kinase phosphorylation, whereas other PKC inhibitors, Ro-32-0432, Go-6976, GF-109203X, and calphostin C, had no effect (Fig. 3A). As shown in Fig. 3B, LPS-induced MMP-9 expression and p38 kinase phosphorylation were reduced in a dose-dependent manner by rottlerin. These observations led us to hypothesize that PKC{delta} acts upstream of p38 kinase in the pathway from LPS to MMP-9 expression in Raw 264.7 cells.



View larger version (43K):
[in this window]
[in a new window]
  		FIGURE 3. LPS is unable to induce MMP-9 expression in the presence of rottlerin. A, Cells were pretreated with rottlerin (2 µM), Ro-32-0432 (0.2 µM), Go-6976 (0.1 µM), GF-109203X (0.1 µM), and calphostin C (0.1 µM) for 30 min before challenge with LPS for 12 h (zymography) or 20 min (immunoblots). Conditioned media and whole-cell lysates were assayed for gelatinolytic activity by zymography and for p38 phosphorylation by Western blotting. B, Cells were incubated in DMEM containing 0.5% FBS with LPS (100 ng/ml) in the presence or the absence of the indicated concentration of rottlerin (0, 2, 5, and 10 µM). The results shown are representative of three independent experiments.

 
LPS induces MMP-9 expression is independent of PKC{delta}

To further examine the role of PKC{delta} in LPS signaling to MMP-9 expression, Raw 264.7 cells were exposed to PMA for 12 h to deplete PKC{delta} and other members of the novel PKC subfamily as well as of the conventional subfamily. Immunoblot analysis revealed that PKC{alpha}, PKC{delta}, and PKC{epsilon} were strongly down-regulated by the prolonged exposure to PMA, whereas PKC{iota} was unaffected (Fig. 4A). To our surprise, MMP-9 expression was not affected by this prolonged PMA treatment (Fig. 4B), suggesting that the induction of MMP-9 by LPS is independent of both conventional and novel isotypes of PKC, including PKC{delta}. To confirm that LPS induces MMP-9 expression independently of PKC{delta}, cells were infected with a retrovirus encoding a kinase-deficient form of PKC{delta}, PKC{delta}-K376R, that acts as a DN mutant (33). As shown in Fig. 4B, cells infected with this virus accumulated MMP-9 as efficiently as the control cells (Fig. 4B), again ruling out the involvement of PKC{delta}. Clearly, the effect of rottlerin on MMP-9 expression is not due to inhibition of PKC{delta}.



View larger version (42K):
[in this window]
[in a new window]
  		FIGURE 4. LPS-induced MMP-9 expression is independent of PKC{delta}. A, PMA-mediated depletion of conventional and novel PKC isozymes was assessed by Western blot analysis with PKC isoform-specific Abs. Data are representative of at least three independent experiments. B, Raw 264.7 cells were infected with retrovirus encoding DN-PKC{delta} and incubated with (or without) PMA (50 ng/ml) for 12 h before challenge with LPS for 12 h. Culture supernatants were analyzed for MMP-9 production by gelatin zymography. They were fractionated by 7.5% SDS-PAGE in 0.2% gelatin and analyzed by zymography, and whole-cell lysates were assayed for p38 kinase by Western blotting. Data are representative of at least three independent experiments.

 
LPS induces p38 kinase and MMP-9 via a ROS pathway

There are reports that rottlerin is a putative mitochondrial uncoupler as well as a PKC{delta} inhibitor (34, 35, 36) and thus potentially affects mitochondrial O2

{cjs1138}

production. We next tested any role of ROS for the expression of MMP-9 and the phosphorylation of p38 kinase in response to LPS. The NADPH oxidase-like flavoenzyme inhibitor DPI was found to block LPS-induced MMP-9 expression and p38 kinase phosphorylation (Fig. 5A). Similarly, the ROS scavenger N-acetylcysteine (NAC) reduced both MMP-9 expression and p38 kinase phosphorylation, suggesting that ROS act upstream of p38 kinase in LPS signaling to MMP-9 expression. However, PDTC, which primarily inhibits NF-{kappa}B, had no inhibitory effect (Fig. 5A). Next, we examined the effect of LPS on levels of ROS using the DCF-DA assay. This assay measures H2O2 indirectly by measuring the DCF generated by H2O2 from DCF-DH. LPS indeed enhanced DCF fluorescence, and this effect was dramatically inhibited by rottlerin (Fig. 5B). It thus appears that LPS stimulates the generation of ROS, and this leads to p38 kinase activation and subsequently to MMP-9 expression.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 5. LPS induces MMP-9 expression via a ROS-dependent pathway. A, Raw 264.7 cells were pretreated with 2 µM DPI, 5 mM NAC, or 50 µM PDTC and exposed to 100 ng/ml LPS for 12 h. Phosphorylation of p38 kinase (upper panel) and the gelatinolytic activity of MMP-9 (lower panel) were analyzed as described in Materials and Methods. B, Cells were exposed to 100 ng/ml LPS for 30 min in the presence or the absence of rottlerin (3 µM). DCF fluorescence was quantified as described in Materials and Methods. Data are expressed as the median fluorescence length. The statistical significance of the ROS measurements was assessed by unpaired t tests (p < 0.05).

 
LPS induces MMP-9 through a mitochondrial ROS-dependent pathway

Besides acting as an NADPH oxidase-like flavoenzyme inhibitor, DPI has also been reported to inhibit mitochondrial complex I (NADH-ubiquinone oxidoreductase), so decreasing oxidative phosphorylation (37). In addition, rotenone and DPI strongly inhibit mitochondrial ROS production in monocytes/macrophages (16, 38). We therefore examined the possible role of mitochondrial ROS in LPS-induced MMP-9 expression. When cells were treated with LPS together with the mitochondrial complex I inhibitor rotenone, little phospho-p38 kinase or MMP-9 was detected. In contrast, the mitochondrial complex II inhibitor thenoyltrifluoroacetone (TTFA) had no effect, and the mitochondrial complex III inhibitor antimycin A had only a slight effect (Fig. 6A). These results suggest that LPS somehow acts primarily through the mitochondrial complex I ROS.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 6. LPS induces ROS generation. A, Upper panel, LPS-induced gelatinolytic activity of MMP-9 was evaluated in the presence or the absence of rotenone (3 µM), TTFA (10 µM), or antimycin A (10 µM). Conditioned media were separated by 7.5% SDS-PAGE containing 0.2% gelatin and analyzed by zymography as described in Materials and Methods. Lower panel, Immunoblots were prepared from whole cell extracts and probed with anti-phospho-p38 kinase and p38 kinase Ab. B, Cells were exposed to 100 ng/ml LPS for 30 min in the presence or the absence of rotenone (5 µM), rottlerin (3 µM), or SB203580 (10 µM). The inhibitors were added 10 min before application of LPS. DHR fluorescence was quantified as described in Materials and Methods. The statistical significance of the ROS measurement was assessed by unpaired t tests (p < 0.05). C, Cells were incubated with LPS (100 ng/ml) in DMEM containing 0.5% FBS for 20 min in the presence or the absence of rottlerin (2 µM) or rotenone (5 µM). To obtain mitochondria-enriched fractions, the cells were disrupted by rapid freezing in liquid nitrogen, followed by differential centrifugation as described in Materials and Methods. Superoxide production was measured in the presence of NADPH for 15 min.

 
To determine whether LPS activates mitochondrial ROS production, we used the DHR assay that is more selective for mitochondrial-derived ROS (39). As shown in Fig. 6B, LPS increased DHR fluorescence in the control cells, whereas there was no increase in the presence of the mitochondrial complex I inhibitor rotenone. To our surprise, rottlerin also attenuated DHR fluorescence, suggesting its potential activity as an antioxidant. Similar to these results, in lucigenin-derived chemiluminescence assays that detect only intramitochondrial O2

{cjs1138}

 production (16), pretreatment with rotenone and rottlerin completely abolished LPS-induced O2

{cjs1138}

 production in a mitochondria-enriched membrane fraction (Fig. 6C), further substantiating that LPS activates mitochondrial ROS production. Consistent with the idea that p38 kinase acts downstream of ROS in LPS signaling to MMP-9 expression, the p38 kinase inhibitor SB203580 had no effect on ROS levels (Fig. 6B).

LPS activates AP-1 activity in a ROS/p38 kinase-dependent manner

We next examined the signaling events after p38 kinase activation. It has been reported that MAPKs activate NF-{kappa}B and AP-1 and that the MMP-9 promoter contains NF-{kappa}B- and AP-1-responsive elements (9, 10). To determine whether LPS activates AP-1 promoter activity, Raw 264.7 cells were transfected with an AP-1-dependent luciferase reporter gene, and their response to LPS was assessed. LPS significantly increased AP-1-dependent luciferase activity, and this effect was severely reduced by pretreatment with rottlerin or SB203580 (Fig. 7). In contrast, PDTC failed to reduce LPS-dependent luciferase activity. Clearly, LPS-dependent activation of AP-1 is correlated with LPS-dependent MMP-9 expression.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 7. LPS-mediated activation of AP-1 correlates with the induction of p38 kinase and MMP-9 expression. Cells were transfected with an AP-1-responsive luciferase reporter gene (pAP-1-Luc). The transfectants were treated with LPS in the presence or the absence of rottlerin (3 µM), SB203580 (10 µM), and PDTC (50 µM), and their relative luciferase activities were measured. Bars depict the mean ± SD of three independent experiments, and the data are expressed as the fold increase relative to the control value.

 
LPS induction of MMP-9 expression is independent of NF-{kappa}B

Next, we examined the effect of LPS on the activation of NF-{kappa}B. LPS clearly induced I{kappa}B{alpha} degradation and consequent NF-{kappa}B stimulation, but pretreatment with rotenone, TTFA, or antimycin A did not inhibit these processes (Fig. 8A), nor did rottlerin or SB203580 (data not shown). Therefore, LPS-induced mitochondrial ROS generation and p38 kinase activation are independent of NF-{kappa}B. We also transfected cells with an NF-{kappa}B-dependent luciferase reporter gene and found that LPS induced NF-{kappa}B luciferase activity essentially as efficiently in the presence of rottlerin or SB203580 as in controls (Fig. 8B). In contrast, it was unable to stimulate NF-{kappa}B luciferase activity in the presence of PDTC, an NF-{kappa}B inhibitor (Fig. 8B). These results together with the earlier data (Fig. 5A) indicate that NF-{kappa}B is not involved in the LPS-induced ROS/p38 kinase cascade leading to MMP-9 expression.



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 8. LPS activates MMP-9 independently of NF-{kappa}B. A, Subconfluent Raw 264.7 cells were incubated with (or without) mitochondrial complex inhibitors for 30 min before challenge with LPS for 20 min. Total cell extracts were separated by 10% SDS-PAGE and immunoblotted with anti-I{kappa}B{alpha} Ab. Data are representative of three separate experiments. B, After transient transfection with pNF-{kappa}B-Luc, Raw 264.7 cells were incubated in DMEM containing 10% FBS for 24 h before being exposed to LPS for 6 h. In some cases the cells were pretreated with rottlerin (3 µM), SB203580 (10 µM), or PDTC (50 µM) for 30 min before addition of LPS (100 ng/ml). Luciferase activities were measured and normalized to cotransfected {beta}-galactosidase activities. Bars depict the mean ± SD of three independent experiments, and the data are expressed as the fold increase relative to the control value.

 
LPS activates the MMP-9 promoter via the ROS/p38 kinase/AP-1 pathway

Finally, the roles of ROS and p38 kinase in LPS-activated MMP-9 expression were examined using a luciferase reporter dependent on the MMP-9 promoter. We found that LPS activated the MMP-9 promoter in cells transfected with this reporter and that DPI, rotenone, rottlerin, and SB203580 dramatically suppressed this effect. These results suggest that mitochondrial ROS and p38 kinase play critical roles in LPS signaling to MMP-9 expression (Fig. 9).



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 9. LPS activates the MMP-9 promoter via a signaling mechanism dependent on ROS and p38 kinase. Raw 264.7 cells were transiently transfected with a pMMP-9-Luc reporter plasmid and incubated for 24 h. They were then incubated for 30 min with rotenone (5 µM), rottlerin (3 µM), SB203580 (10 µM), or PDTC (50 µM) before stimulation with LPS (100 ng/ml) or control buffer for 6 h. Relative luciferase activities were determined as described in Fig. 8. Bars depict the mean ± SD of three independent experiments, and the data are expressed as the fold increase relative to the control value.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The results of the present study suggest that LPS signaling to MMP-9 expression is dependent on mitochondria-derived ROS and on subsequent activation of p38 kinase and AP-1 in Raw 264.7 macrophages. LPS, a bacterial endotoxin, has potent proinflammatory properties and acts on many cell types, including macrophages, endothelial cells, and fibroblasts (40, 41). Although it elicits the expression of several proinflammatory mediators, including IL-1, IL-6, IL-8, and TNF-{alpha} (42, 43), the intracellular signaling pathway leading to the accumulation of cellular proteases such as MMP-9 is not well understood, especially with regard to the roles of ROS and p38 kinase. There is evidence that G proteins (44), phospholipase C (45), protein kinase A, and PKC (46) are involved in LPS responses. In addition, a number of Src family tyrosine kinases become activated in LPS-stimulated macrophages, and inhibition of tyrosine phosphorylation blocks the secretion of proinflammatory cytokines and MMP-9 (47). Previous reports have shown that LPS increases MMP-9 production by activating the ERK subgroup of MAPKs as well as p38 kinase in monocytes, astrocytes, and neutrophils (48, 49, 50).

Initially, we thought, based on the results obtained with rottlerin, a putative PKC{delta} inhibitor, that PKC{delta} participated in LPS-induced MMP-9 expression. However, because long term PMA treatment and DN-PKC{delta} overexpression did not affect LPS-induced MMP-9 expression (Fig. 4), we concluded that the inhibitory effect of rottlerin on MMP-9 expression was independent of PKC{delta}. Importantly, we were able to show that pretreatment with DPI, NAC, or rotenone, a specific inhibitor of mitochondrial complex I, dramatically reduced LPS-induced p38 kinase phosphorylation and MMP-9 expression (Figs. 5A and 9). Because DPI and rotenone have also been shown to inhibit mitochondrial complex I activity and reduce mitochondrial ROS production (16, 37, 38), it is conceivable that mitochondrial ROS are downstream components of LPS signaling. In agreement with this idea, we showed that LPS increased ROS levels and that pretreatment with rotenone completely blocked that effect (Fig. 5B and Fig. 6, B and C). It is puzzling that rottlerin reduces mitochondrial ROS levels, because uncouplers would be expected to increase O2 consumption and the flux of electrons through the electron transport system, thereby increasing the production of ROS at the level of reduction of molecular oxygen. However, the precise action of mitochondrial uncouplers on ROS production remains to be clarified. Interestingly, Parthasarathi et al. (38) reported that carbonyl cyanide p-trifluoromethoxyphenylhydrazone, another type of mitochondrial uncoupler, strongly inhibits mitochondrial Ca2+ and ROS generation in response to TNF-{alpha}; this suggests that the effect of an uncoupler on levels of mitochondrial ROS could vary with the cell type or agonist used. In addition, we cannot rule out the possibility that the inhibitory effect of rottlerin on mitochondrial ROS is due to an antioxidant action, independent of any activity as an uncoupler. In any event, to determine whether other reactive species, e.g., NO or NADPH oxidase-derived ROS, are also involved in LPS signaling to MMP-9, we tested the effects of NG-monomethyl-L-arginine, a NO synthase and NADPH oxidase inhibitor, on this pathway. We found that it had no effect, suggesting that NO is not involved (data not shown). LPS treatment also failed to induce the phagocytic NADPH oxidase system (data not shown).

Mitochondrial ROS have been implicated in signaling in response to a variety of treatments that induce gene transcription (20, 38), and other workers have also shown that p38 kinase is activated by intracellular ROS as well as by exogenously administered H2O2 (51, 52, 53, 54). Hypoxia can also lead to p38 kinase activation (55), although neither the mechanism underlying this activation nor its relationship to ROS has been clarified. In the case of hypoxia, mitochondrial ROS are thought to be responsible for triggering p38 kinase phosphorylation and gene expression (55). Mitochondrial ROS production can be harmful, because it abolishes the mitochondrial potential and leads to the release of cytochrome c and apoptosis (14, 56). However, as far as we could determine, the levels of ROS attained in our experiments were not cytotoxic (data not shown), suggesting that the LPS-induced mitochondrial ROS production observed is an intrinsic, not a pathological, feature of cell signaling. The mechanism by which ROS induces p38 kinase activation is not clear, but a cascade linked to mitochondrial ROS and p38 kinase is also believed to mediate angiotensinogen expression in response to high glucose in kidney tubule cells (20).

We also examined the nuclear targets of activated p38 kinase. Transcription of MMP-9 is usually regulated by inflammatory cytokines such as TNF-{alpha} and IL-1, whereas MMP-2 is constitutive in many cell types (57, 58). The MMP-9 promoter has both NF-{kappa}B and AP-1 binding sites, whereas the MMP-2 promoter does not contain any AP-1 binding site, and this difference may be related to their differential regulation (59). Usually, ROS production in response to external stimuli is associated with activation of AP-1 and NF-{kappa}B. To assess how ROS generated in mitochondria contribute to the LPS signaling, we measured NF-{kappa}B and AP-1 activity in response to LPS. Because NF-{kappa}B has been suggested to be a key transcription factor regulating MMP-9 expression (59, 60, 61, 62, 63), we asked whether LPS induces MMP-9 via the NF-{kappa}B pathway in addition to activating p38 kinase. Our data show that LPS-dependent activation of NF-{kappa}B is unrelated to the activation of ROS and p38 kinase. We also demonstrated that rottlerin, rotenone, and SB203580 had no inhibitory effect on LPS-induced I{kappa}B{alpha} degradation and NF-{kappa}B reporter gene activity, whereas PDTC inhibited it strongly, indicating that the ROS-p38 kinase-linked cascade represents an alternative signaling pathway leading to MMP-9 expression that does not involve NF-{kappa}B (Fig. 8). Likewise, application of rottlerin and SB203580 reduced the activation of AP-1 by LPS (Fig. 7) and also strongly inhibited LPS-induced MMP-9 promoter activity in the Raw 264.7 cells, indicating that the mitochondrial ROS-p38 kinase pathway regulates LPS-induced MMP-9 expression via AP-1 (Fig. 7).

Similar to our results, the p38 kinase signal transduction pathway has been shown to stimulate MMP-9 expression in an AP-1-dependent fashion in human vascular smooth muscle cells (64); more importantly, Sano et al. (51) have reported that IL-6 is induced by angiotensin II in cardiac fibroblasts via a ROS-p38 kinase-dependent, not an NF-{kappa}B-dependent, pathway. Hence a mitochondrial ROS-p38 kinase-AP-1 cascade may exist in certain cell types in addition to Raw 264.7 cells, mediating specific signaling reactions in response to a limited number of agonists. The reason why this cascade is confined to certain cases is not clear, but may be related to the unique reaction of certain cell types, including monocytes, to mitochondrial electron transport inhibitors such as rotenone and antimycin A.

Recently, Yoo et al. (60) reported that IL-1{beta} up-regulates MMP-9 expression in RAW 264.7 cells via the production of ROS and subsequent activation of NF-{kappa}B. However, we could not detect any MMP-9 up-regulation in response to IL-1{beta} in our experimental conditions (data not shown). Those authors did not show by zymography or Western blotting that NF-{kappa}B inhibitors such as PDTC actually blocked IL-1{beta}-induced MMP-9 up-regulation (60). They did observe that NAC inhibited MMP-9 promoter activity, but it may also have inhibited activation of AP-1, as suggested by our results. As in our case, Yoo et al. (60) observed that DCF-sensitive ROS production played a critical role in the signaling pathway to MMP-9 expression, although the source of the ROS was not defined. In view of the undoubted role of the mitochondrial ROS-p38-AP-1 pathway in MMP-9 up-regulation in response to LPS in the present study, we speculate that the ROS detected by Yoo et al. (60) was also mitochondrial.

In conclusion, we showed that redox-regulated p38 phosphorylation and subsequent AP-1 activation appear to be critical for LPS-induced MMP-9 expression, at least in Raw 264.7 cells. Future studies elucidating the linkage between mitochondrial ROS-p38 kinase and AP-1 will probably be pivotal to our complete understanding of LPS-evoked intracellular signaling to MMP-9 expression and inflammatory response.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by a Korea Research Foundation Grant (KRF-2003-041-C20227), the Signaling Research Center program (Aging and Apoptosis Research Center) 2002 of the Korea Science and Engineering Foundation, the BioDiscovery Research Program, and the Frontier 21 Programs (Proteomics; to J.-H.K.) of the Korea Ministry of Science and Technology. Back

2 Current address: Gonda Department of Cell and Molecular Biology, House Ear Institute, University of Southern California, Los Angeles, CA 90057. Back

3 Address correspondence and reprint requests to Dr. Jae-Hong Kim, School of Life Sciences and Biotechnology, Korea University, 5-1 Anam-dong, Sungbuk-gu, Seoul 136-701, Korea. E-mail address: jhongkim{at}korea.ac.kr Back

4 Abbreviations used in this paper: MMP, matrix metalloproteinase; DCFH-DA, 2',7'-dichlorofluorescein diacetate; DN, dominant negative; DPI, diphenyleneiodonium chloride; HIF, hypoxia-inducible factor; NAC, N-acetylcysteine; PKC, protein kinase C; ROS, reactive oxygen species; TTFA, thenoyltrifluoroacetone. Back

Received for publication January 21, 2004. Accepted for publication October 1, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Coussens, L. M., B. Fingleton, L. M. Matrisian. 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387.[Abstract/Free Full Text]
  2. Ellerbroek, S. M., M. S. Stack. 1999. Membrane associated matrix metalloproteinases in metastasis. BioEssays 21:940.[Medline]
  3. Brinckerhoff, C. E., L. M. Matrisian. 2002. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 3:207.[Medline]
  4. Vihinen, P., V. M. Kahari. 2002. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 99:157.[Medline]
  5. Westermarck, J., V. M. Kahari. 1999. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13:781.[Abstract/Free Full Text]
  6. Visse, R., H. Nagasse. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92:827.[Abstract/Free Full Text]
  7. Hoshino, M., Y. Nakamura, J. Sim, J. Shimojo, S. Isogai. 1998. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J. Allergy Clin. Immunol. 102:783.[Medline]
  8. Curry, T. E., Jr, K. G. Osteen. 2003. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr. Rev. 24:428.[Abstract/Free Full Text]
  9. Sato, H., M. Seiki. 1993. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8:395.[Medline]
  10. Gum, R., M. Lengyel, J. Juarez, J. H. Chen, H. Sato, M. Seiki, D. Boyd. 1996. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J. Biol. Chem. 271:10672.[Abstract/Free Full Text]
  11. Sen, C. K., L. Packer. 1996. Antioxidant and redox regulation of gene transcription. FASEB J. 10:709.[Abstract]
  12. Rhee, S. G.. 1999. Redox signaling: hydrogen peroxide as intracellular messenger. Exp. Mol. Med. 31:53.[Medline]
  13. Bowie, A., L. A. O’Neill. 2000. Oxidative stress and nuclear factor-{kappa}B activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol. 59:13.[Medline]
  14. Quillet-Mary, A., J. Jaffrézou, V. Mansat, C. Bordier, J. Naval, G. Laurent. 1997. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J. Biol. Chem. 272:21388.[Abstract/Free Full Text]
  15. Hancock, J. T., C. T. Jones. 1987. The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. Biochem. J. 242:103.[Medline]
  16. Li, Y., M. A. Trush. 1998. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem. Biophys. Res. Commun. 253:295.[Medline]
  17. Haddad, J. J.. 2002. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell. Signal. 14:879.[Medline]
  18. Dumont, A., S. P. Hehner, T. G. Hofmann, M. Ueffing, W. Droge, M. L. Schmitz. 1999. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-{kappa}B. Oncogene 18:747.[Medline]
  19. Chandel, N. S., D. S. McClintock, C. E. Feliciano, T. M. Wood, J. A. Melendez, A. M. Rodriguez, P. T. Schumacker. 2000. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1{alpha} during hypoxia: a mechanism of O2 sensing. J. Biol. Chem. 275:25130.[Abstract/Free Full Text]
  20. Hsieh, T. J., S. L. Zhang, J. G. Filep, S. S. Tang, J. R. Ingelfinger, J. S. D. Chan. 2002. High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology 143:2975.[Abstract/Free Full Text]
  21. Martiny-Baron, G., M. G. Kazanietz, H. Mischak, P. M. Blumberg, G. Kochs, H. Hug, D. Marme, C. Schachtele. 1993. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö6976. J. Biol. Chem. 268:9194.[Abstract/Free Full Text]
  22. Gschwendt, M., H. J. Muller, K. Kielbassa, R. Zang, W. Kittstein, G. Rincke, F. F. Marks. 1994. Rottlerin, a novel protein kinase inhibitor. Biochem. Biophys. Res. Commun. 199:93.[Medline]
  23. Jarvis, W. D., A. J. Turner, L. F. Povirk, R. S. Traylor, S. Grant. 1994. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res. 54:1707.[Abstract/Free Full Text]
  24. Means, T. K., R. P. Pavlovich, D. Roca, M. W. Vermeulen, M. J. Fenton. 2000. Activation of TNF-{alpha} transcription utilizes distinct MAP kinase pathways in different macrophage populations. J. Leukocyte Biol. 67:885.[Abstract]
  25. Cuenda, A., J. Rouse, Y. N. Doza, R. Meier, P. Cohen, T. F. Gallagher, P. R. Young, J. C. Lee. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interlukin-1. FEBS Lett. 364:229.[Medline]
  26. Bennett, B. L., D. T. Sasaki, B. W. Murray, E. C. O'Leary, S. T. Sakata, W. Xu, J. C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, et al 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98:13681.[Abstract/Free Full Text]
  27. Schreck, R., B. Meier, D. N. Männel, W. Dröge, P. A. Baeuerle. 1992. Dithiocarbamates as potent inhibitors of nuclear factor {kappa}B activation in intact cells. J. Exp. Med. 175:1181.[Abstract/Free Full Text]
  28. Higgins, D. S., J. T. Greenamyre. 1996. [3H]Dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study. J. Neurosci. 16:3807.[Abstract/Free Full Text]
  29. Woo, C. H., M. H. Yoo, H. J. You, S. H. Cho, Y. C. Mun, C. M. Seong, J. H. Kim. 2003. Transepithelial migration of neutrophils in response to leukotriene B4 is mediated by a reactive oxygen species-extracellular signal-regulated kinase-linked cascade. J. Immunol. 170:6273.[Abstract/Free Full Text]
  30. Woo, C. H., Y. W. Eom, M. H. Yoo, H. J. You, H. J. Han, W. K. Song, Y. J. Yoo, J. S. Chun, J. H. Kim. 2000. Tumor necrosis factor-{alpha} generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. J. Biol. Chem. 275:32357.[Abstract/Free Full Text]
  31. Genersch, E., K. Hayess, Y. Neuenfeld, H. Haller. 2000. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J. Cell Sci. 113:(Pt. 23):4319.[Abstract]
  32. Simon, C., H. Goepfert, D. Boyd. 1998. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res. 58:1135.[Abstract/Free Full Text]
  33. Braiman, L., A. Alt, T. Kuroki, M. Ohba, A. Bak, T. Tennenbaum, S. R. Sampson. 1999. Protein kinase C-{delta} mediates insulin-induced glucose transport in primary cultures of rat skeletal muscle. Mol. Endocrinol. 13:2002.[Abstract/Free Full Text]
  34. Soltoff, S. P.. 2001. Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and indirectly blocks protein kinase C-{delta} tyrosine phosphorylation. J. Biol. Chem. 276:37986.[Abstract/Free Full Text]
  35. Kayali, A. G., D. A. Austin, N. J. Webster. 2002. Rottlerin inhibits insulin-stimulated glucose transport in 3T3–L1 adipocytes by uncoupling mitochondrial oxidative phosphorylation. Endocrinology 143:3884.[Abstract/Free Full Text]
  36. Tillman, D. M., K. Izeradjene, K. S. Szucs, L. Douglas, J. A. Houghton. 2003. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res. 63:5118.[Abstract/Free Full Text]
  37. Holland, P. C., M. G. Clark, D. P. Bloxham, H. A. Lardy. 1973. Mechanism of action of the hypoglycemic agent diphenyleneiodonium. J. Biol. Chem. 248:6050.[Abstract/Free Full Text]
  38. Parthasarathi, K., H. Ichimura, S. Quadri, A. Issekutz, J. Bhattacharya. 2002. Mitochondrial reactive oxygen species regulate spatial profile of proinflammatory responses in lung venular capillaries. J. Immunol. 169:7078.[Abstract/Free Full Text]
  39. Deshpande, S. S., P. Angkeow, J. Huang, M. Ozaki, K. Irani. 2000. Rac1 inhibits TNF-{alpha}-induced endothelial cell apoptosis: dual regulation by reactive oxygen species. FASEB J. 14:1705.[Abstract/Free Full Text]
  40. Fenton, M. J., D. T. Golenbock. 1998. LPS-binding proteins and receptors. J. Leukocyte Biol. 64:25.[Abstract]
  41. Morrison, D. C., R. J. Ulevitch. 1978. The effects of bacterial endotoxins on host mediation systems. Am. J. Pathol. 93:526.[Medline]
  42. Yang, R. B., M. R. Mark, A. Gray, A. Huang, M. H. Xie, M. Zhang, A. Goddard, W. I. Wood, A. L. Gurney, P. J. Godowski. 1998. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling. Nature 395:284.[Medline]
  43. Wong, P. M. C., S. W. Chung, B. M. Sultzer. 2000. Genes, receptors, signals and responses to lipopolysaccharide endotoxin. Scand. J. Immunol. 51:123.[Medline]
  44. Daniel-Issakani, S., A. M. Spiegel, B. Strulovici. 1989. Lipopolysaccharide response is linked to the GTP binding protein, Gi2, in the promonocytic cell line U937. J. Biol. Chem. 264:20240.[Abstract/Free Full Text]
  45. Chen, T. Y., M. G. Lei, T. Suzuki, D. C. Morrison. 1992. Lipopolysaccharide receptors and signal transduction pathways in mononuclear phagocytes. Curr. Top. Microbiol. Immunol. 181:169.[Medline]
  46. Shapira, L., S. Takashiba, C. Champagne, S. Amar, T. E. Van Dyke. 1994. Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-{alpha} and IL-1{beta} production by human monocytes. J. Immunol. 153:1818.[Abstract]
  47. Scherle, P. A., E. A. Jones, M. F. Favata, A. J. Daulerio, M. B. Covington, S. A. Nurnberg, R. L. Magolda, J. M. Trzaskos. 1998. Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J. Immunol. 161:5681.[Abstract/Free Full Text]
  48. Lee, W. J., C. Y. Shin, B. K. Yoo, J. R. Ryu, E. Y. Choi, J. H. Cheong, J. H. Ryu, K. H. Ko. 2003. Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 41:15.[Medline]
  49. Underwood, D. C., R. R. Osborn, S. Bochnowicz, E. F. Webb, D. J. Rieman, J. C. Lee, A. M. Romanic, J. L. Adams, D. W. Hay, D. E. Griswold. 2000. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. 279:L895.
  50. Lai, W. C., M. Zhou, U. Shankavaram, G. Peng, L. M. Wahl. 2003. Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J. Immunol. 170:6244.[Abstract/Free Full Text]
  51. Sano, M., K. Fukuda, T. Sato, H. Kawaguchi, M. Suematsu, S. Matsuda, S. Koyasu, H. Matsui, K. Yamauchi-Takihara, M. Harada, et al 2001. ERK and p38 MAPK, but not NF-{kappa}B, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ. Res. 89:661.[Abstract/Free Full Text]
  52. Herrera, B., M. Fernandez, C. Roncero, J. J. Ventura, A. Porras, A. Valladares, M. Benito, I. Fabregat. 2001. Activation of p38 MAPK by TGF-{beta} in fetal rat hepatocytes requires radical oxygen production, but is dispensable for cell death. FEBS Lett. 499:225.[Medline]
  53. Hashimoto, S., Y. Gon, K. Matsumoto, I. Takeshita, T. Horie. 2001. N-acetylcysteine attenuates TNF-{alpha}-induced p38 MAP kinase activation and p38 MAP kinase-mediated IL-8 production by human pulmonary vascular endothelial cells. Br. J. Pharmacol. 132:270.[Medline]
  54. Dabrowski, A., C. Boguslowicz, M. Dabrowska, I. Tribillo, A. Gabryelewicz. 2000. Reactive oxygen species activate mitogen-activated protein kinases in pancreatic acinar cells. Pancreas 21:376.[Medline]
  55. Kulisz, A., N. Chen, N. S. Chandel, Z. Shao, P. T. Schumacker. 2000. Mitochondrial ROS initiate phosphorylation of p38 MAP kinase during hypoxia in cardiomyocytes. Am. J. Physiol. Lung Cell Mol. Physiol. 282:L1324.
  56. Yang, J., X. Liu, K. Bhalla, C. N. Kim, A. M. Ibrado, J. Cai, T. I. Peng, D. P. Jones, X. Wang. 1997. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129.[Abstract/Free Full Text]
  57. Cao, J., A. Rehemtulla, W. Bahou, S. Zucker. 1996. Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J. Biol. Chem. 271:30174.[Abstract/Free Full Text]
  58. Tomasek, J. J., N. L. Halliday, D. L. Updike, J. S. Ahern-Moore, T. K. Vu, R. W. Liu, E. W. Howard. 1997. Gelatinase activation is regulated by the organization of the polymerized actin cytoskeleton. J. Biol. Chem. 272:7482.[Abstract/Free Full Text]
  59. Matrisian, L. M.. 1994. Matrix metalloproteinase gene expression. Ann. NY Acad. Sci. 732:42.[Medline]
  60. Yoo, H. G., B. A. Shin, J. S. Park, K. H. Lee, K. O. Chay, S. Y. Yang, B. W. Ahn, Y. D. Jung. 2002. IL-1{beta} induces MMP-9 via reactive oxygen species and NF-{kappa}B in murine macrophage RAW 264.7 cells. Biochem. Biophys. Res. Commun. 298:251.[Medline]
  61. Kolev, K., J. Skopal, L. Simon, E. Csonka, R. Machovich, Z. Nagy. 2003. Matrix metalloproteinase-9 expression in post-hypoxic human brain capillary endothelial cells: H2O2 as a trigger and NF-{kappa}B as a signal transducer. Thromb. Haemost. 90:528.[Medline]
  62. Moon, S. K., B. Y. Cha, C. H. Kim. 2004. ERK1/2 mediates TNF-{alpha}-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-{kappa}B and AP-1: involvement of the ras dependent pathway. J. Cell Physiol. 198:417.[Medline]
  63. Hah, N., S. T. Lee. 2003. An absolute role of the PKC-dependent NF-{kappa}B activation for induction of MMP-9 in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 305:428.[Medline]
  64. Simon, C., M. Simon, G. Vucelic, M. J. Hicks, P. K. Plinkert, A. Koitschev, H. P. Zenner. 2001. The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp. Cell Res. 271:344.[Medline]



This article has been cited by other articles:


Home page
 J. Neurosci.Home page
Y. Hayashi, M. Yoshida, M. Yamato, T. Ide, Z. Wu, M. Ochi-Shindou, T. Kanki, D. Kang, K. Sunagawa, H. Tsutsui, et al.
Reverse of Age-Dependent Memory Impairment and Mitochondrial DNA Damage in Microglia by an Overexpression of Human Mitochondrial Transcription Factor A in Mice
J. Neurosci., August 20, 2008; 28(34): 8624 - 8634.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Lemarie, E. Bourdonnay, C. Morzadec, O. Fardel, and L. Vernhet
Inorganic Arsenic Activates Reduced NADPH Oxidase in Human Primary Macrophages through a Rho Kinase/p38 Kinase Pathway
J. Immunol., May 1, 2008; 180(9): 6010 - 6017.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Liang, J. Wang, A. Azfer, W. Song, G. Tromp, P. E. Kolattukudy, and M. Fu
A Novel CCCH-Zinc Finger Protein Family Regulates Proinflammatory Activation of Macrophages
J. Biol. Chem., March 7, 2008; 283(10): 6337 - 6346.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Gomez-Pina, A. Soares-Schanoski, A. Rodriguez-Rojas, C. del Fresno, F. Garcia, M. T. Vallejo-Cremades, I. Fernandez-Ruiz, F. Arnalich, P. Fuentes-Prior, and E. Lopez-Collazo
Metalloproteinases Shed TREM-1 Ectodomain from Lipopolysaccharide-Stimulated Human Monocytes
J. Immunol., September 15, 2007; 179(6): 4065 - 4073.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T.-N. Zhu, H.-J. He, S. Kole, T. D'Souza, R. Agarwal, P. J. Morin, and M. Bernier
Filamin A-mediated Down-regulation of the Exchange Factor Ras-GRF1 Correlates with Decreased Matrix Metalloproteinase-9 Expression in Human Melanoma Cells
J. Biol. Chem., May 18, 2007; 282(20): 14816 - 14826.
[Abstract] [Full Text] [PDF]
</

 Home page
 J. Biol. Chem.Home page
A. D. Sheftel, S. F. Kim, and P. Ponka
Non-heme Induction of Heme Oxygenase-1 Does Not Alter Cellular Iron Metabolism
J. Biol. Chem., April 6, 2007; 282(14): 10480 - 10486.
[Abstract] [Full Text] [PDF]